Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 31

1.

The Role of Activator Protein-1 (AP-1) Family Members in CD30-Positive Lymphomas.

Garces de Los Fayos Alonso I, Liang HC, Turner SD, Lagger S, Merkel O, Kenner L.

Cancers (Basel). 2018 Mar 28;10(4). pii: E93. doi: 10.3390/cancers10040093. Review.

2.

The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma.

Schleussner N, Merkel O, Costanza M, Liang HC, Hummel F, Romagnani C, Durek P, Anagnostopoulos I, Hummel M, Jöhrens K, Niedobitek A, Griffin PR, Piva R, Sczakiel HL, Woessmann W, Damm-Welk C, Hinze C, Stoiber D, Gillissen B, Turner SD, Kaergel E, von Hoff L, Grau M, Lenz G, Dörken B, Scheidereit C, Kenner L, Janz M, Mathas S.

Leukemia. 2018 Mar 28. doi: 10.1038/s41375-018-0045-9. [Epub ahead of print]

PMID:
29588546
3.

Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.

Snijder B, Vladimer GI, Krall N, Miura K, Schmolke AS, Kornauth C, Lopez de la Fuente O, Choi HS, van der Kouwe E, Gültekin S, Kazianka L, Bigenzahn JW, Hoermann G, Prutsch N, Merkel O, Ringler A, Sabler M, Jeryczynski G, Mayerhoefer ME, Simonitsch-Klupp I, Ocko K, Felberbauer F, Müllauer L, Prager GW, Korkmaz B, Kenner L, Sperr WR, Kralovics R, Gisslinger H, Valent P, Kubicek S, Jäger U, Staber PB, Superti-Furga G.

Lancet Haematol. 2017 Dec;4(12):e595-e606. doi: 10.1016/S2352-3026(17)30208-9. Epub 2017 Nov 15.

4.

First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia.

Boidol B, Kornauth C, van der Kouwe E, Prutsch N, Kazianka L, Gültekin S, Hoermann G, Mayerhoefer ME, Hopfinger G, Hauswirth A, Panny M, Aretin MB, Hilgarth B, Sperr WR, Valent P, Simonitsch-Klupp I, Moriggl R, Merkel O, Kenner L, Jäger U, Kubicek S, Staber PB.

Blood. 2017 Dec 7;130(23):2499-2503. doi: 10.1182/blood-2017-05-785683. Epub 2017 Sep 27.

PMID:
28972014
5.

When the guardian sleeps: Reactivation of the p53 pathway in cancer.

Merkel O, Taylor N, Prutsch N, Staber PB, Moriggl R, Turner SD, Kenner L.

Mutat Res. 2017 Jul;773:1-13. doi: 10.1016/j.mrrev.2017.02.003. Epub 2017 Feb 17. Review.

PMID:
28927521
6.

Insights into the Pathogenesis of Anaplastic Large-Cell Lymphoma through Genome-wide DNA Methylation Profiling.

Hassler MR, Pulverer W, Lakshminarasimhan R, Redl E, Hacker J, Garland GD, Merkel O, Schiefer AI, Simonitsch-Klupp I, Kenner L, Weisenberger DJ, Weinhaeusel A, Turner SD, Egger G.

Cell Rep. 2016 Oct 4;17(2):596-608. doi: 10.1016/j.celrep.2016.09.018.

7.

JAK-STAT signaling in cancer: From cytokines to non-coding genome.

Pencik J, Pham HT, Schmoellerl J, Javaheri T, Schlederer M, Culig Z, Merkel O, Moriggl R, Grebien F, Kenner L.

Cytokine. 2016 Nov;87:26-36. doi: 10.1016/j.cyto.2016.06.017. Epub 2016 Jun 24. Review.

PMID:
27349799
8.

Breaking a paradigm: IL-6/STAT3 signaling suppresses metastatic prostate cancer upon ARF expression.

Culig Z, Pencik J, Merkel O, Kenner L.

Mol Cell Oncol. 2016 Apr 4;3(2):e1090048. doi: 10.1080/23723556.2015.1090048. eCollection 2016 Mar.

9.

Anaplastic large cell lymphoma arises in thymocytes and requires transient TCR expression for thymic egress.

Malcolm TI, Villarese P, Fairbairn CJ, Lamant L, Trinquand A, Hook CE, Burke GA, Brugières L, Hughes K, Payet D, Merkel O, Schiefer AI, Ashankyty I, Mian S, Wasik M, Turner M, Kenner L, Asnafi V, Macintyre E, Turner SD.

Nat Commun. 2016 Jan 12;7:10087. doi: 10.1038/ncomms10087.

10.

Interleukin-6 receptor alpha blockade improves skin lesions in a murine model of systemic lupus erythematosus.

Birner P, Heider S, Petzelbauer P, Wolf P, Kornauth C, Kuroll M, Merkel O, Steiner G, Kishimoto T, Rose-John S, Soleiman A, Moriggl R, Kenner L.

Exp Dermatol. 2016 Apr;25(4):305-10. doi: 10.1111/exd.12934. Epub 2016 Feb 13. Erratum in: Exp Dermatol. 2017 May;26(5):467.

11.

STAT3 regulated ARF expression suppresses prostate cancer metastasis.

Pencik J, Schlederer M, Gruber W, Unger C, Walker SM, Chalaris A, Marié IJ, Hassler MR, Javaheri T, Aksoy O, Blayney JK, Prutsch N, Skucha A, Herac M, Krämer OH, Mazal P, Grebien F, Egger G, Poli V, Mikulits W, Eferl R, Esterbauer H, Kennedy R, Fend F, Scharpf M, Braun M, Perner S, Levy DE, Malcolm T, Turner SD, Haitel A, Susani M, Moazzami A, Rose-John S, Aberger F, Merkel O, Moriggl R, Culig Z, Dolznig H, Kenner L.

Nat Commun. 2015 Jul 22;6:7736. doi: 10.1038/ncomms8736. Erratum in: Nat Commun. 2015;6:8802.

12.

AF1q is a novel TCF7 co-factor which activates CD44 and promotes breast cancer metastasis.

Park J, Schlederer M, Schreiber M, Ice R, Merkel O, Bilban M, Hofbauer S, Kim S, Addison J, Zou J, Ji C, Bunting ST, Wang Z, Shoham M, Huang G, Bago-Horvath Z, Gibson LF, Rojanasakul Y, Remick S, Ivanov A, Pugacheva E, Bunting KD, Moriggl R, Kenner L, Tse W.

Oncotarget. 2015 Aug 21;6(24):20697-710.

13.

p53-dependent non-coding RNA networks in chronic lymphocytic leukemia.

Blume CJ, Hotz-Wagenblatt A, Hüllein J, Sellner L, Jethwa A, Stolz T, Slabicki M, Lee K, Sharathchandra A, Benner A, Dietrich S, Oakes CC, Dreger P, te Raa D, Kater AP, Jauch A, Merkel O, Oren M, Hielscher T, Zenz T.

Leukemia. 2015 Oct;29(10):2015-23. doi: 10.1038/leu.2015.119. Epub 2015 May 14.

PMID:
25971364
14.

Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation.

Merkel O, Hamacher F, Griessl R, Grabner L, Schiefer AI, Prutsch N, Baer C, Egger G, Schlederer M, Krenn PW, Hartmann TN, Simonitsch-Klupp I, Plass C, Staber PB, Moriggl R, Turner SD, Greil R, Kenner L.

J Pathol. 2015 Aug;236(4):445-56. doi: 10.1002/path.4539. Epub 2015 Apr 27.

15.

JunB and PTEN in prostate cancer: 'loss is nothing else than change'.

Birner P, Egger G, Merkel O, Kenner L.

Cell Death Differ. 2015 Apr;22(4):522-3. doi: 10.1038/cdd.2014.232. No abstract available.

16.

Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma.

Weilemann A, Grau M, Erdmann T, Merkel O, Sobhiafshar U, Anagnostopoulos I, Hummel M, Siegert A, Hayford C, Madle H, Wollert-Wulf B, Fichtner I, Dörken B, Dirnhofer S, Mathas S, Janz M, Emre NC, Rosenwald A, Ott G, Lenz P, Tzankov A, Lenz G.

Blood. 2015 Jan 1;125(1):124-32. doi: 10.1182/blood-2014-08-594507. Epub 2014 Oct 30.

17.

MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis.

Benner A, Mansouri L, Rossi D, Majid A, Willander K, Parker A, Bond G, Pavlova S, Nückel H, Merkel O, Ghia P, Montserrat E, Kaderi MA, Rosenquist R, Gaidano G, Dyer MJ, Söderkvist P, Linderholm M, Oscier D, Tvaruzkova Z, Pospisilova S, Dührsen U, Greil R, Döhner H, Stilgenbauer S, Zenz T; European Research Initiative on CLL (ERIC).

Haematologica. 2014 Aug;99(8):1285-91. doi: 10.3324/haematol.2013.101170.

18.

Anaplastic large cell lymphoma-propagating cells are detectable by side population analysis and possess an expression profile reflective of a primitive origin.

Moti N, Malcolm T, Hamoudi R, Mian S, Garland G, Hook CE, Burke GA, Wasik MA, Merkel O, Kenner L, Laurenti E, Dick JE, Turner SD.

Oncogene. 2015 Apr 2;34(14):1843-52. doi: 10.1038/onc.2014.112. Epub 2014 May 12.

PMID:
24814516
19.

PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas.

Laimer D, Dolznig H, Kollmann K, Vesely PW, Schlederer M, Merkel O, Schiefer AI, Hassler MR, Heider S, Amenitsch L, Thallinger C, Staber PB, Simonitsch-Klupp I, Artaker M, Lagger S, Turner SD, Pileri S, Piccaluga PP, Valent P, Messana K, Landra I, Weichhart T, Knapp S, Shehata M, Todaro M, Sexl V, Höfler G, Piva R, Medico E, Ruggeri BA, Cheng M, Eferl R, Egger G, Penninger JM, Jaeger U, Moriggl R, Inghirami G, Kenner L.

Nat Med. 2012 Nov;18(11):1699-704. doi: 10.1038/nm.2966. Epub 2012 Oct 14.

20.

Novel treatment avenues for peripheral T-cell lymphomas.

Hopfinger G, Griessl R, Sifft E, Taylor N, Kenner L, Greil R, Merkel O.

Expert Opin Drug Discov. 2012 Dec;7(12):1149-63. doi: 10.1517/17460441.2012.727392. Epub 2012 Sep 24. Review.

PMID:
22998641

Supplemental Content

Loading ...
Support Center